Save Product
Product Details
Source
Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.
Clone
1B10
Species
Mouse
Isotype
Human IgG1 | Human Kappa
Conjugate
Unconjugated
Antibody Type
Recombinant Monoclonal
Reactivity
Virus
Immunogen
Recombinant Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE) derived from human 293 cells
Specificity
This product is a specific antibody specifically reacts with Glycoprotein E/gE (VZV).
Application
ApplicationRecommended UsageELISA0.1-8 ng/mLPurity
90% as determined by SDS-PAGE.
95% as determined by SEC-MALS.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.
Please contact us for customized product forms or formulations.
Reconstitution
Please refer to the Certificate of Analysis (CoA) for specific instructions.
For best performance, we strongly recommend following the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored in a lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
SEC-MALS
The purity of Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) is more than 95% and the molecular weight of this protein is around 135-155 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) at 1 μg/mL (100 μL/well) can bind Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) with a linear range of 0.1-1 ng/mL (QC tested).
Protocol
Immobilized Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) on Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) precoated (0.2 μg/well) plate can bind Biotinylated Monoclonal Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (4G2) (Cat. No. VZV-BLM545)at 0.25 μg/mL (100 μL/well) with a linear range of 0.2-8 ng/mL (Routinely tested).
Protocol
Bioactivity-SPR
Anti-Glycoprotein E (VZV) Antibody, Human IgG1 (1B10) (Cat. No. VZV-M544) captured on Protein A Chip can bind Varicella zoster virus (strain Oka vaccine) Envelope Glycoprotein E (gE), His Tag (Cat. No. GLE-V52H3) with an affinity constant of 5.63 nM as determined in SPR assay (Biacore 8K) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Glycoprotein E (gE) is one of the known glycoproteins (gB, gC, gE, gH, gI, gK, gI) of VZV that is most abundantly expressed on the surface of virus and infected cells, playing an important role in viral replication and cell-to-cell spread. The strongly immunogenic gE can provide strong IgG signal in body fluid, which makes it ideal to be developed as an antigen for analysis of IgG antibodies. gE also demonstrates high potency as a vaccine immunogen and is formulated as the single viral envelope protein that constitutes the GSK VZV recombinant subunit vaccine Shingrix®.
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
